Dr Laeeq Malik

Medical Oncologist
Become a Patient

Dr Laeeq Malik specialises in providing personalised, patient-centred cancer care based on cancer characteristics, general health and most importantly, patient preferences. He is driven by a strong sense of responsibility for providing high quality care with direct focus on issues related to overall wellbeing. Dr Malik has a clear belief that a systemic approach to cancer management with shared decision making is most beneficial to cancer patients.


Dr Laeeq Malik is a medical oncologist at Icon Cancer Centre Canberra. He undertook physician and specialist oncology training in Australia before relocating to the United States to complete a two-year research fellowship in advanced oncology drug development at the University of Texas. During his fellowship in San Antonio he was mentored by Professor Steve Weitman who had a strong impact and influence on how he delivers patient-centred care.

Dr Malik has a strong background in clinical research with a particular interest in conducting early phase clinical trials. He has participated as local principal investigator and co-principal investigator on a number of studies and is currently the Director of Medical Oncology Clinical Trials at Canberra Hospital. Dr Malik has collaborated on several research projects with scientists from the University of Canberra and Australian National University. He serves as a reviewer for a number of oncology journals and has authored numerous peer-reviewed articles (over journal 35 papers), chapters and abstracts at international meetings.

Dr Malik is a clinical lecturer at the Australian National University, teaching and mentoring medical students in clinical skills and research. He supervises the medical oncology trainee teaching program at Canberra Hospital and has previously co-supervised and mentored a number of junior doctors who have successfully completed their speciality training.

In addition to his role at Icon, Dr Malik is a staff specialist in medical oncology at Canberra Hospital, visiting medical oncologist at Calvary Hospital, National Capital Private Hospital and South East Regional Hospital. His clinical experience covers a broad range of solid tumour malignancies with special clinical interest in early phase clinical trials, breast cancer, prostate cancer, genitourinary cancer, testicular cancer, bladder cancer and renal cancer.

Affiliations & Memberships

  • American Association for Cancer Research (AACR)
  • American Society of Clinical Oncology (ASCO)
  • Medical Oncology Group of Australia (MOGA)
  • Royal Australasian College of Physicians (RACP)

Special Interests

Dr Laeeq Malik accepts referrals for all cancer types, with a special clinical interest in:
  • Breast cancer
  • Genitourinary cancer
  • Prostate cancer

Icon Locations

Canberra View centre

Visiting Locations

  • Calvary Hospital
  • Canberra Hospital
  • National Capital Private Hospital
  • South East Regional Hospital


  • Real‐world impact of anti‐HER2 therapy‐related cardiotoxicity in patients with advanced HER2‐positive breast cancer. Conduit, R.H. de Boer, S. Lok, P. Gibbs, L. Malik, Z. Loh, B. Yeo, S. Greenberg, B. Devitt, J. Lombard, M. Nottage, I. Collins, J. Torres, M. Nolan & L. Nott. Asia‐Pacific Journal of Clinical Oncology, 2020.

  • Impact of prior (neo) adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer. Y. Kanjanapan, S.W. Lok, P. Gibbs, R. De Boer, B. Yeo, S. Greenberg, F. Barnett, L. Nott, G. Richardson, R. Wong, M. Nottage, I.M. Collins, J. Torres, J. Lombard, J. Johns, M. Harold & L. Malik. Breast Cancer Research and Treatment, 2020; 1-9.

  • Association between tyrosine‐kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer. M. Gadd, G. Pranavan & L. Malik. Cancer Reports, 2020; e1275.

  • Targeting nuclear LSD1 to reprogram cancer cells and reinvigorate exhausted T cells via a novel LSD1-EOMES switch. W.J. Tu, R.D. McCuaig, A.HY Tan, K. Hardy, N. Seddiki, S.Ali, J.E. Dahlstrom, E.G. Bean, J. Dunn, J. Forwood, S. Tsimbalyuk, K. Smith, D. Yip, L. Malik, T. Prasanna, P. Milburn & S. Rao. Frontiers in Immunology, 2020; 11: 1128.

  • Increasing complexity in oncology phase I clinical trials. L. Malik & D. Lu. Investigational New Drugs, 2019; 37(3): 519-523.